blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2411412

EP2411412 - HUMANIZED ANTIBODIES AGAINST LIGHT AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.04.2016
Database last updated on 25.09.2024
Most recent event   Tooltip13.07.2018Lapse of the patent in a contracting state
State(s) deleted from list of lapses: MT		published on 15.08.2018  [2018/33]
Applicant(s)For all designated states
Teva Biopharmaceuticals USA, Inc.
9410 Key West Avenue
Rockville, MD 20850 / US
[2012/05]
Inventor(s)01 / SMITH, Rodger
9410 Key West Avenue
Rockville, MD 20850 / US
02 / KANAKARAJ, Palanisamy
9410 Key West Avenue
Rockville, MD 20850 / US
03 / COOKSEY, Bridget, A.
9410 Key West Avenue
Rockville, MD 20850 / US
04 / ROSCHKE, Viktor
9410 Key West Avenue
Rockville, MD 20850 / US
05 / ROSEN, Craig
9410 Key West Avenue
Rockville, MD 20850 / US
 [2015/22]
Former [2012/05]01 / SMITH, Rodger
9410 Key West Avenue
Rockville MD 20850 / US
02 / KANAKARAJ, Palanisamy
9410 Key West Avenue
Rockville MD 20850 / US
03 / COOKSEY, Bridget, A.
9410 Key West Avenue
Rockville MD 20850 / US
04 / ROSCHKE, Viktor
9410 Key West Avenue
Rockville MD 20850 / US
05 / ROSEN, Craig
9410 Key West Avenue
Rockville MD 20850 / US
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2012/05]O'Brien, Simon Warwick
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Application number, filing date10710753.422.03.2010
WO2010US28144
Priority number, dateUS20090202661P24.03.2009         Original published format: US 202661 P
[2012/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010111180
Date:30.09.2010
Language:EN
[2010/39]
Type: A1 Application with search report 
No.:EP2411412
Date:01.02.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 30.09.2010 takes the place of the publication of the European patent application.
[2012/05]
Type: B1 Patent specification 
No.:EP2411412
Date:27.05.2015
Language:EN
[2015/22]
Search report(s)International search report - published on:EP30.09.2010
ClassificationIPC:A61K47/48, G01N33/53, C07K16/28
[2014/46]
CPC:
C07K16/2875 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/16 (EP); A61P11/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P25/00 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P9/10 (EP);
G01N33/53 (US); C07K2317/24 (EP,US); C07K2317/34 (EP,US) (-)
Former IPC [2012/05]C07K16/28
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/05]
Extension statesALNot yet paid
BANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:HUMANISIERTE ANTIKÖRPER GEGEN LICHT UND ANWENDUNGEN DAVON[2012/05]
English:HUMANIZED ANTIBODIES AGAINST LIGHT AND USES THEREOF[2012/05]
French:ANTICORPS HUMANISÉS DIRIGÉS CONTRE LE POLYPEPTIDE LIGHT ET LEURS UTILISATIONS[2012/05]
Entry into regional phase17.10.2011National basic fee paid 
17.10.2011Designation fee(s) paid 
17.10.2011Examination fee paid 
Examination procedure17.10.2011Examination requested  [2012/05]
11.05.2012Amendment by applicant (claims and/or description)
29.06.2012Despatch of a communication from the examining division (Time limit: M06)
24.12.2012Reply to a communication from the examining division
20.05.2014Date of oral proceedings
03.07.2014Despatch of a communication from the examining division (Time limit: M02)
03.07.2014Minutes of oral proceedings despatched
03.09.2014Reply to a communication from the examining division
19.12.2014Communication of intention to grant the patent
10.04.2015Receipt of the translation of the claim(s)
20.04.2015Fee for grant paid
20.04.2015Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.06.2012
Opposition(s)01.03.2016No opposition filed within time limit [2016/18]
Fees paidRenewal fee
23.03.2012Renewal fee patent year 03
26.03.2013Renewal fee patent year 04
21.03.2014Renewal fee patent year 05
24.03.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.03.2010
AT27.05.2015
BE27.05.2015
CY27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
MC27.05.2015
MK27.05.2015
NL27.05.2015
PL27.05.2015
RO27.05.2015
SE27.05.2015
SI27.05.2015
SK27.05.2015
SM27.05.2015
TR27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
[2018/31]
Former [2018/29]HU22.03.2010
AT27.05.2015
BE27.05.2015
CY27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
MC27.05.2015
MK27.05.2015
MT27.05.2015
NL27.05.2015
PL27.05.2015
RO27.05.2015
SE27.05.2015
SI27.05.2015
SK27.05.2015
SM27.05.2015
TR27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2018/28]HU22.03.2010
AT27.05.2015
BE27.05.2015
CY27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
MC27.05.2015
MK27.05.2015
MT27.05.2015
NL27.05.2015
PL27.05.2015
RO27.05.2015
SE27.05.2015
SI27.05.2015
SK27.05.2015
SM27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2017/40]AT27.05.2015
BE27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
MC27.05.2015
MT27.05.2015
NL27.05.2015
PL27.05.2015
RO27.05.2015
SE27.05.2015
SI27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/49]AT27.05.2015
BE27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
MC27.05.2015
PL27.05.2015
RO27.05.2015
SI27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/37]AT27.05.2015
BE27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
PL27.05.2015
RO27.05.2015
SI27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/24]AT27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
PL27.05.2015
RO27.05.2015
SI27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/21]AT27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
IT27.05.2015
LT27.05.2015
LV27.05.2015
PL27.05.2015
RO27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/10]AT27.05.2015
CZ27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
PL27.05.2015
RO27.05.2015
SK27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/09]AT27.05.2015
DK27.05.2015
EE27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2016/07]AT27.05.2015
DK27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2015/51]AT27.05.2015
ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2015/50]ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
BG27.08.2015
NO27.08.2015
GR28.08.2015
IS27.09.2015
PT28.09.2015
Former [2015/49]ES27.05.2015
FI27.05.2015
HR27.05.2015
LT27.05.2015
LV27.05.2015
NO27.08.2015
GR28.08.2015
PT28.09.2015
Cited inInternational search[I]WO03089575  (HUMAN GENOME SCIENCES INC [US], et al) [I] 1-30 * The whole document, in particular;; examples 1-3 *;
 [I]WO2008027338  (KIRIN PHARMA KK [JP], et al) [I] 1-30 * The whole document, in particular;; examples 1-7 *;
 [AP]  - Sanofi Aventis Press Dept., "Sanofi-aventis and Kyowa Hakko Kirinenter into a Collaboration and Licensing Agreementon an Anti LIGHT fully human monoclonal antibody", (20090514), Sanofi-aventis.com, URL: http://en.sanofi-aventis.com/binaries/20090514_kirin-khk_en_en_tcm28-25122.pdf, (20100629), XP007913657 [AP] 1-30 * the whole document *
 [A]  - WANG JING ET AL, "Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy.", JOURNAL OF CLINICAL INVESTIGATION, (200403), vol. 113, no. 6, ISSN 0021-9738, pages 826 - 835, XP009135527 [A] 1-30 * the whole document *
 [A]  - YU PING ET AL, "Priming of naive T cells inside tumors leads to eradication of established tumors", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/NI1029, (20040201), vol. 5, no. 2, ISSN 1529-2908, pages 141 - 149, XP009130369 [A] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1038/ni1029
 [A]  - MOREL Y ET AL, "Reciprocal Expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: Light down-regulates its own receptor", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20001015), vol. 165, ISSN 0022-1767, pages 4397 - 4404, XP002197451 [A] 1-30 * the whole document *
 [A]  - HARROP J A ET AL, "HERPESVIRUS ENTRY MEDIATOR LIGAND (HVEM-L), A NOVEL LIGAND FOR HVEM/TR2, STIMULATES PROLIFERATION OF T CELLS AND INHIBITS HT29 CELL GROWTH", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.273.42.27548, (19981016), vol. 273, no. 42, ISSN 0021-9258, pages 27548 - 27556, XP002947574 [A] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.273.42.27548
 [A]  - MAURI D N ET AL, "LIGHT, A NEW MEMBER OF THE TNF SUPERFAMILY AND LYMPHOTOXIN ALPHA ARE LIGANDS FOR HERPESVIRUS ENTRY MEDIATOR", IMMUNITY, CELL PRESS, US LNKD- DOI:10.1016/S1074-7613(00)80455-0, (19980121), vol. 8, ISSN 1074-7613, pages 21 - 30, XP002947575 [A] 1-30 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1074-7613(00)80455-0
Examination   - UNIPROT, "Alignment of human and cynomolgous monkey LIGHT/TNFSF14", (20140114), URL: http://www.uniprot.org/align/201401142BG9K5IXNO, (20140114), XP055096438
by applicantUS4444887
 WO8605807
 US4694778
 EP0239400
 US4716111
 US4741900
 WO8901036
 US4816567
 US4816397
 WO8912624
 US4946778
 EP0396387
 US4980286
 WO9109967
 WO9110741
 WO9114438
 US5116964
 WO9208495
 US5122464
 EP0519596
 US5225538
 US5225539
 US5258498
 EP0592106
 US5314995
 US5413923
 US5530101
 US5545806
 US5565332
 US5569825
 WO9634096
 WO9633735
 US5585089
 US5589369
 US5591669
 US5625126
 US5633425
 US5658570
 US5661016
 US5693761
 US5693762
 US5693780
 US5736137
 WO9816654
 US5756096
 WO9824893
 US5807715
 US5811524
 US5814318
 WO9846645
 WO9850433
 WO9852976
 US5892019
 US5939598
 US6075181
 WO0034317
 US6150584
 US6180370
 US6190370
 US6193980
 US6413777
 US6420140
 US2002123057
 US6458592
 US2003157641
    - HAMERS-CASTERMAN ET AL., NATURE, (1993), vol. 363, pages 446 - 448
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - CHOTHIA ET AL., J MOI. BIOL., (1987), vol. 196, pages 901 - 917
    - ROUX ET AL., J. IMMUNOL, (1998), vol. 161, page 4083
    - HARLOW ET AL., Antibodies: A Laboratory Manual, COLD SPRING HARBOR LABORATORY PRESS, (1988), pages 27 - 28
    - Posttranslational Covalent Modification Of Proteins, ACADEMIC PRESS, (1983), pages 1 - 12
    - SEIFTER ET AL., METH ENZYMOL, (1990), vol. 182, pages 626 - 646
    - RATTAN ET AL., ANN NYACAD SCI, (1992), vol. 663, pages 48 - 62
    - GASCOIGNE ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 54, pages 2936 - 2940
    - CAPON ET AL., NATURE, (1989), vol. 337, pages 525 - 531
    - TRAUNECKER ET AL., NATURE, (1989), vol. 339, pages 68 - 70
    - ZETTMEISSL ET AL., DNA CELL BIOL. USA, (1990), vol. 9, pages 347 - 353
    - BYRN ET AL., NATURE, (1990), vol. 344, pages 667 - 670
    - WATSON ET AL., J. CELL. BIOL., (1990), vol. 110, pages 2221 - 2229
    - WATSON ET AL., NATURE, (1991), vol. 349, pages 164 - 167
    - ARUFFO ET AL., CELL, (1990), vol. 57, pages 1303 - 1313
    - LINSLEY ET AL., J. EXP. MED., (1991), vol. 773, pages 721 - 730
    - LISLEY ET AL., J. EXP. MED., (1991), vol. 174, pages 561 - 569
    - STAMENKOVIC, CELL, (1991), vol. 66, pages 1133 - 1144
    - ASHKENAZI ET AL., PROC. NATL. ACAD. SCI USA, (1991), vol. 55, pages 10535 - 10539
    - LESSLAUER ET AL., EUR. J. IMMUNOL., (1991), vol. 27, pages 2883 - 2886
    - PEPPEL ET AL., J. EXP. MED., (1991), vol. 774, pages 1483 - 1489
    - RIDGWAY; GORMAN, J. CELL. BIOL., (1991), vol. 115
    - LEONG, S.R. ET AL., CYTOKINE, (2001), vol. 16, page 106
    - ADV. IN DRUG DELIV. REV., (2002), vol. 54, page 531
    - WEIR ET AL., RIOCHEM. SOC. TRANSACTIONS, (2002), vol. 30, page 512
    - GENTZ ET AL., PROC. NATL. ACAD. SCI USA, (1989), vol. 55, pages 821 - 824
    - WILSON ET AL., CELL, (1984), vol. 37, page 161
    - BRIZZARD, BIOTECHNIQUES, (1994), vol. 16, no. 4, pages 730 - 735
    - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 56
    - "Antibodies For Drug Delivery", HCLLSTROM ET AL., Controlled Drug Delivery, MARCEL DEKKER, INC., (1987), pages 623 - 53
    - "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE, Monoclonal Antibodies '84: Biological And Clinical Applications, (1985), pages 475 - 506
    - "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 16
    - THORPE ET AL., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., (1982), vol. 52, pages 119 - 58
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 57, pages 6851 - 6855
    - MORRISON ET AL., ADV. IMMUNOL., (1988), vol. 44, pages 65 - 92
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - PADLAN, MOLEC. IMMUN., (1991), vol. 25, pages 489 - 498
    - PADLAN, MOLEC. IMMUN., (1994), vol. 31, pages 169 - 217
    - HAMMERLING ET AL., Monoclonal Antibodies and T- Cell Hybridomas, ELSEVIER, (1981), pages 563 - 681
    - BIRD, SCIENCE, (1988), vol. 242, pages 423 - 442
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 55, pages 5879 - 5883
    - WARD ET AL., NATURE, (1989), vol. 334, pages 544 - 554
    - SKERRA ET AL., SCIENCE, (1988), vol. 242, pages 1038 - 1041
    - HUSTON ET AL., METHODS IN ENZYMOLOGY, (1991), vol. 203, pages 46 - 88
    - SHU ET AL., PROC. NATL. SCI. USA, (1993), vol. 90, pages 1995 - 1999
    - SKERRA ET AL., SCIENCE, (1988), vol. 240, pages 1038 - 1040
    - MORRISON, SCIENCE, (1985), vol. 229, page 1202
    - OI ET AL., BIOTECHNIQUES, (1986), vol. 4, page 214
    - GILLIES ET AL., J. IMMUNOL. METHODS, (1989), vol. 125, pages 191 - 202
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323
    - PADLAN, MOLECULAR IMMUNOLOGY, (1991), vol. 28, no. 4, 5, pages 489 - 498
    - STUDNICKA ET AL., PROTEIN ENGINEERING, (1994), vol. 7, no. 6, pages 805 - 814
    - ROGUSKA ET AL., PROC. NATL. SCI. USA, (1994), vol. 91, pages 969 - 973
    - LONBERG; HUSZAR, INT. REV. IMMUNOL., (1995), vol. 73, pages 65 - 93
    - JESPERS ET AL., BIOLTECHNOLOGY, (1988), vol. 72, pages 899 - 903
    - CHOTHIA ET AL., J. MOL. BIOL., (1998), vol. 278, pages 457 - 479
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), pages 85 I - 855
    - NEUBERGER ET AL., NATURE, (1984), vol. 372, pages 604 - 608
    - TAKEDA ET AL., NATURE, (1985), vol. 314, pages 452 - 454
    - NEWMAN, BIOTECHNOLOGY, (1992), vol. 10, pages 1455 - 1460
    - PROUDFOOT, NATURE, (1986), vol. 322, page 52
    - KOHLER, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, page 2197
    - "Mammalian Expression Vectors", RIDGWAY, A. A. G., Vectors, BUTTERWORTHS, (1988), pages 470 - 472
    - FOECKING ET AL., GENE, (1986), vol. 5, page 101
    - COCKETT ET AL., BIO/TECHNOTOGY, (1990), vol. 8, page 2
    - WIGLER ET AL., CELL, (1977), vol. 11, page 223
    - SZYBALSKA; SZYBALSKI, PROC. NATL. ACAD. SCI. USA, (1992), vol. 48, page 202
    - LOWY ET AL., CELL, (1980), vol. 22, page 817
    - WIGLER ET AL., NATL. ACUD. SCI. USA, (1980), vol. 77, page 357
    - O'HARE ET AL., PROC. NATL. ACAD. SCI USA, (1981), vol. 78, page 1527
    - MULLIGAN; BERG, PROC. NATL. ACAD. SCI USA, (1981), vol. 78, page 2072
    - WU; WU, BIOTHERAPY, (1991), vol. 3, pages 87 - 95
    - SANTERRE ET AL., GENE, (1984), vol. 30, page 147
    - COLBERRE-GARAPIN ET AL., J MOL. BIOL., (1981), vol. 150, page 1
    - DNA cloning, ACADEMIC PRESS, (1987), vol. 3
    - GROUSE ET AL., MOL. CELL. BIOL., (1983), vol. 3, page 257
    - RUTHER ET AL., EMBO J., (1983), vol. 2, page 1791
    - INOUYE; INOUYE, NUCLEIC ACIDS RES., (1985), vol. 73, pages 3101 - 3109
    - VAN HEEKE; SCHUSTER, J. BIOL. CHEM., (1989), vol. 24, pages 5503 - 5509
    - STINCHCOMB ET AL., NATURE, (1979), vol. 252, page 39
    - KINGSMAN ET AL., GENE, (1979), vol. 7, page 141
    - TSCHEMPER ET AL., GENE, (1980), vol. 10, page 157
    - JONES, GENETICS, (1977), vol. 85, page 12
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - TREAT ET AL., Liposomes in the Therapy of Infectious Disease and Cancer, LISS, (1989), pages 353 - 365
    - SEFTON, CRC CRIT. REF BIOMED. ENG., (1987), vol. 14, page 201
    - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
    - SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
    - RANGER; PEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., (1983), vol. 23, page 61
    - LEVY ET AL., SCIENCE, (1985), vol. 228, page 190
    - DURING ET AL., ANN. NEUROL., (1989), vol. 25, page 351
    - HOWARD ET AL., J. NEUROSURG., (1989), vol. 71, page 105
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 1864 - 1868
    - WU; WU, J BIOL. CHEM., (1987), vol. 262, pages 4429 - 4432
    - JONES ET AL., NATURE, (19860529), vol. 321, no. 6069, pages 522 - 5
    - ROGUSKA ET AL., PROTEIN ENGINEERING, (1996), vol. 9, no. 10, pages 895 - 904
    - STUDNICKA ET AL., "Humanizing Mouse Antibody Frameworks While Preserving 3-D Structure", PROTEIN ENGINEERING, (1994), vol. 7, page 805
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.